Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin + Temozolomide in Recurrent Glioblastoma
NCT02315534Phase 2Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Mar 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of napabucasin in glioblastoma (GBM), sponsored by Sumitomo Pharma America. Started Mar 2015; status: completed.
02
Drugs
napabucasin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02315534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02315534.